A new concentrate of clotting factors II, VII, IX and X, made from pooled human plasma collected in citrate anticoagulant by a process involving the adsorption of the effluent from Cohn fraction I on ...

The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates. A phase 3 trial of valoctocogene roxaparvovec, ...

ATLANTA, Georgia — It's a problem many clinicians would love to have: a whole variety of new or emerging therapeutic options to use in the care of their patients. In a session titled "Hemophilia ...

Rare clotting factor deficiencies are a collection of bleeding disorders associated with issues with clotting factors. These conditions are inherited and target the proteins in the blood that control ...

Blood clotting represents one of the body’s most elegant and complex protective mechanisms. This intricate process involves numerous proteins working in precise sequence – often described as a ...